• September 12, 2019
  • Source: Authority Magazine
Catherine Ivy was recently interviewed for Authority Magazine's latest "Social Impact Heroes" series where she opened up about her 14-year journey to accelerate drug discovery for brain tumor patients, a recent success story from the Ivy Center's Phase 0 clinical trials program, and what our community, society and politicians can do to help address the unmet needs of patients battling aggressive brain tumors.
  • August 26, 2019
The Ivy Brain Tumor Center at the Barrow Neurological Institute and Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), today announced a collaborative partnership to test Salarius’ therapeutic candidate, Seclidemstat, for the treatment of glioblastoma.
  • July 26, 2019
  • Source: TrialSiteNews
The Ivy Brain Tumor Center at the Barrow Neurological Institute recently completed a Phase 0 clinical trial of the breast cancer drug ribociclib (Kisqali) for the treatment of recurrent glioblastoma. The Ivy recently received $50 million to combat brain cancer. This new drug cocktail represents one of the potential weapons in humankind’s war against this killer disease.
  • July 26, 2019
Barrow Neurological Foundation led a fundraising effort that raised more than $539,000 for brain cancer research at the Ivy Brain Tumor Center on the first ever Glioblastoma Awareness Day, July 17, 2019.
  • July 25, 2019
The Ivy Brain Tumor Center at the Barrow Neurological Institute has released the results of its recent Phase 0 clinical trial of the breast cancer drug ribociclib (Kisqali®) for the treatment of recurrent glioblastoma.
  • July 16, 2019
  • Source: Newsweek
Newsweek's cover story examines the rising success of precision medicine to fight once-untreatable tumors and highlights our efforts in using this method to fight glioblastoma where speed and personalization are key.
  • July 15, 2019
  • Source: FierceBiotech
The Ivy Brain Tumor’s goal is to try to speed advances into the clinic by testing potential therapies on tumor samples taken from patients who are currently battling glioblastoma—an approach its researchers hope will shed some light on the potential of Karyopharm’s new drug in treating the disease.
  • July 11, 2019
The Ivy Brain Tumor Center at the Barrow Neurological Institute has announced a partnership with Karyopharm Therapeutics (Nasdaq:KPTI) to accelerate the treatment of brain cancer.
  • May 14, 2019
  • Source: MedCity News
"Our philosophy is that it is as important to fail fast as it is to succeed quickly," said Nader Sanai, the director of the Ivy Brain Tumor Center at Barrow Neurological Institute.
  • April 26, 2019
  • Source: Chamber Business News
In the heart of Phoenix, a team of doctors is vigilantly working to find a cure for Glioblastoma (GBM), the deadliest form of brain cancer.